Literature DB >> 33355618

Association of the V122I Transthyretin Amyloidosis Genetic Variant With Cardiac Structure and Function in Middle-aged Black Adults: Coronary Artery Risk Development in Young Adults (CARDIA) Study.

Arjun Sinha1,2, Yinan Zheng2, Drew Nannini2, Yishu Qu2, Lifang Hou2, Sanjiv J Shah1,3, Clyde W Yancy1,4, Elizabeth M McNally5,6, Myriam Fornage7, Joao Lima8, Donald M Lloyd-Jones1,2, Laura J Rasmussen-Torvik2, Sadiya S Khan1,2.   

Abstract

IMPORTANCE: The variant V122I is commonly enriched in the transthyretin (TTR) gene in individuals of African ancestry and associated with greater risk of heart failure (HF) in older adulthood, after age 65 years. Prevention of HF may be most effective earlier in life, but whether screening with echocardiography can identify subclinical cardiac abnormalities during middle age to risk-stratify individuals appears to be unknown.
OBJECTIVE: To examine the association between the V122I TTR variant and cardiac structure and function during middle age in those without prevalent HF. DESIGN, SETTING, AND PARTICIPANTS: This serial cross-sectional study of 875 Black participants in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort was conducted at 4 urban sites across the US. Recruiting was completed in 1985-1986, and follow-up examinations occurred 25 and 30 years later. A subset of Black adults from the CARDIA cohort who underwent TTR genotyping was included. Data analysis was completed from January 2020 to October 2020. EXPOSURES: The V122I TTR genotype. MAIN OUTCOMES AND MEASURES: Echocardiographic left ventricular (LV) circumferential and longitudinal systolic strain and LV structure, measured at years 25 and 30 of follow-up. The analyses were adjusted for age, sex, echocardiography quality, genetic ancestry, and field center.
RESULTS: Among the 875 Black adults (mean [SD] age, 49.4 [3.8] years at year 25; 543 women [62.1%]), there were 31 individuals who were heterozygous and 1 who was homozygous for the V122I TTR variant. Of the adults who had an echocardiogram at year 25, rates of hypertension (312 [46%]), diabetes (102 [15%]), and current smoking (128 [19%]) were not significantly different between those who did and did not carry V122I TTR. At year 25, there was no difference in LV circumferential strain, longitudinal strain, or LV structure between those who did vs did not carry V122I TTR. At year 30, those who carried V122I TTR had significantly lower absolute LV circumferential strain (mean [SD], 12.4 [4.2] percentage units) compared with those who did not carry the variant (mean [SD], 14.5 [3.7] percentage units). Those who carried V122I TTR also had significantly higher LV mass index values (mean [SD], 97.5 [34.1] g/m2) compared with those who did not (mean [SD], 83.7 [22.6] g/m2) at year 30. CONCLUSIONS AND RELEVANCE: Carrier status for the V122I TTR variant is associated with subclinical cardiac abnormalities in middle age (worse LV systolic function and higher LV mass) that have been associated with increased risk of incident HF. Midlife screening of individuals who carry V122I TTR with echocardiography may prognosticate risk of symptomatic HF and inform prevention strategies.

Entities:  

Year:  2020        PMID: 33355618      PMCID: PMC7758832          DOI: 10.1001/jamacardio.2020.6623

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  15 in total

1.  Inference of population structure using multilocus genotype data.

Authors:  J K Pritchard; M Stephens; P Donnelly
Journal:  Genetics       Date:  2000-06       Impact factor: 4.562

2.  Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance.

Authors:  Julio A Chirinos; Patrick Segers; Marc L De Buyzere; Richard A Kronmal; Muhammad W Raja; Dirk De Bacquer; Tom Claessens; Thierry C Gillebert; Martin St John-Sutton; Ernst R Rietzschel
Journal:  Hypertension       Date:  2010-05-10       Impact factor: 10.190

3.  Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis.

Authors:  Dermot Phelan; Patrick Collier; Paaladinesh Thavendiranathan; Zoran B Popović; Mazen Hanna; Juan Carlos Plana; Thomas H Marwick; James D Thomas
Journal:  Heart       Date:  2012-08-03       Impact factor: 5.994

4.  Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies.

Authors:  Joel Buxbaum; Alice Alexander; James Koziol; Clement Tagoe; Ervin Fox; Dalane Kitzman
Journal:  Am Heart J       Date:  2010-05       Impact factor: 4.749

Review 5.  The Impact of Direct-to-Consumer Genetic Testing on Patient and Provider.

Authors:  Mary Beth Palko Dinulos; Stephanie E Vallee
Journal:  Clin Lab Med       Date:  2020-01-07       Impact factor: 1.935

Review 6.  Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy?

Authors:  Maximilian L Müller; Javed Butler; Bettina Heidecker
Journal:  Eur J Heart Fail       Date:  2020-01-07       Impact factor: 15.534

7.  Quality Control and Reproducibility in M-Mode, Two-Dimensional, and Speckle Tracking Echocardiography Acquisition and Analysis: The CARDIA Study, Year 25 Examination Experience.

Authors:  Anderson C Armstrong; Erin P Ricketts; Christopher Cox; Paul Adler; Alexander Arynchyn; Kiang Liu; Ellen Stengel; Stephen Sidney; Cora E Lewis; Pamela J Schreiner; James M Shikany; Kimberly Keck; Jamie Merlo; Samuel S Gidding; João A C Lima
Journal:  Echocardiography       Date:  2014-11-09       Impact factor: 1.724

8.  The amyloidogenic V122I transthyretin variant in elderly black Americans.

Authors:  C Cristina Quarta; Joel N Buxbaum; Amil M Shah; Rodney H Falk; Brian Claggett; Dalane W Kitzman; Thomas H Mosley; Kenneth R Butler; Eric Boerwinkle; Scott D Solomon
Journal:  N Engl J Med       Date:  2015-01-01       Impact factor: 91.245

9.  CARDIA: study design, recruitment, and some characteristics of the examined subjects.

Authors:  G D Friedman; G R Cutter; R P Donahue; G H Hughes; S B Hulley; D R Jacobs; K Liu; P J Savage
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

10.  Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry.

Authors:  Scott M Damrauer; Kumardeep Chaudhary; Judy H Cho; Lusha W Liang; Edgar Argulian; Lili Chan; Amanda Dobbyn; Marie A Guerraty; Renae Judy; Jenna Kay; Rachel L Kember; Michael G Levin; Aparna Saha; Tielman Van Vleck; Shefali S Verma; JoEllen Weaver; Noura S Abul-Husn; Aris Baras; Julio A Chirinos; Brian Drachman; Eimear E Kenny; Ruth J F Loos; Jagat Narula; John Overton; Jeffrey Reid; Marylyn Ritchie; Giorgio Sirugo; Girish Nadkarni; Daniel J Rader; Ron Do
Journal:  JAMA       Date:  2019-12-10       Impact factor: 56.272

View more
  5 in total

1.  Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population.

Authors:  Julia Kozlitina; Sonia Garg; Mark H Drazner; Susan A Matulevicius; Colby Ayers; John Overton; Jeffrey Reid; Aris Baras; Krishnasree Rao; Ambarish Pandey; Jarett Berry; James A de Lemos; Justin L Grodin
Journal:  J Card Fail       Date:  2021-10-09       Impact factor: 5.712

2.  Association of Transthyretin Val122Ile Variant With Incident Heart Failure Among Black Individuals.

Authors:  Vibhu Parcha; Gargya Malla; Marguerite R Irvin; Nicole D Armstrong; Suzanne E Judd; Leslie A Lange; Mathew S Maurer; Emily B Levitan; Parag Goyal; Garima Arora; Pankaj Arora
Journal:  JAMA       Date:  2022-04-12       Impact factor: 157.335

3.  Heart Failure, Precision Medicine, and Incremental Equity: The Case of Hereditary Amyloid Cardiomyopathy.

Authors:  Melvin R Echols; Herman Taylor
Journal:  JAMA       Date:  2022-04-12       Impact factor: 157.335

4.  High-avidity binding drives nucleation of amyloidogenic transthyretin monomer.

Authors:  Li Gao; Xinfang Xie; Pan Liu; Jing Jin
Journal:  JCI Insight       Date:  2022-04-08

Review 5.  ATTR Amyloidosis: Current and Emerging Management Strategies: JACC: CardioOncology State-of-the-Art Review.

Authors:  Jan M Griffin; Julie L Rosenthal; Justin L Grodin; Mathew S Maurer; Martha Grogan; Richard K Cheng
Journal:  JACC CardioOncol       Date:  2021-10-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.